An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results